The M-T hook structure is critical for design of HIV-1 fusion inhibitors

Journal of Biological Chemistry

Volumn 287, Issue 41, 2012, Pages 34558-34568

  Chong, Huihui ^a   Yao, Xue ^a   Sun, Jianping ^a   Qiu, Zonglin ^a   Zhang, Meng ^a   Waltersperger, Sandro ^b   Wang, Meitian ^b   Cui, Sheng ^a   He, Yuxian ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b PAUL SCHERRER INSTITUTE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-HIV ACTIVITY; BINDING AFFINITIES; BUNDLE FORMATION; CELL FUSIONS; FUSION INHIBITORS; HIGH RESOLUTION CRYSTAL STRUCTURE; KEY DETERMINANTS; N-TERMINALS; VIRUS ENTRY;

BINDING ENERGY; DISEASES; PEPTIDES; VIRUSES;

HOOKS;

CP 621 652; ENFUVIRTIDE; HUMAN IMMUNODEFICIENCY VIRUS 1 FUSION INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; METHIONINE; METHIONINE 626; THREONINE; THREONINE 627; UNCLASSIFIED DRUG;

AMINO ACID COMPOSITION; AMINO TERMINAL SEQUENCE; ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CELL FUSION; CONFORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; HUMAN IMMUNODEFICIENCY VIRUS 1; M T HOOK; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STABILITY; PROTEIN STRUCTURE; THERMOSTABILITY; VIRUS ENTRY; VIRUS INHIBITION; VIRUS REPLICATION;

CELL LINE; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV-1; HUMANS; PEPTIDES; PROTEIN STABILITY; PROTEIN STRUCTURE, SECONDARY; VIRUS INTERNALIZATION; VIRUS REPLICATION;

EID: 84867242967     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.390393     Document Type: Article

References (45)

1. Eckert, D. M., and Kim, P. S. (2001) Mechanisms of viral membrane fusion and its inhibition. Annu. Rev. Biochem. 70, 777-810 (Pubitemid 32662225)
2. Colman, P. M., and Lawrence, M. C. (2003) The structural biology of type I viral membrane fusion. Nat. Rev. Mol. Cell Biol. 4, 309-319 (Pubitemid 36383957)
3. Zhu, P., Liu, J., Bess, J., Jr., Chertova, E., Lifson, J. D., Grisé, H., Ofek, G. A., Taylor, K. A., and Roux, K. H. (2006) Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 441, 847-852
4. Harrison, S. C. (2008) Viral membrane fusion. Nat. Struct. Mol. Biol. 15, 690-698
5. Chan, D. C., Fass, D., Berger, J. M., and Kim, P. S. (1997) Core structure of gp41 from the HIV envelope glycoprotein. Cell 89, 263-273 (Pubitemid 27199898)
6. Tan, K., Liu, J., Wang, J., Shen, S., and Lu, M. (1997) Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc. Natl. Acad. Sci. U.S.A. 94, 12303-12308 (Pubitemid 27492523)
7. Weissenhorn, W., Dessen, A., Harrison, S. C., Skehel, J. J., and Wiley, D. C. (1997) Atomic structure of the ectodomain from HIV-1 gp41. Nature 387, 426-430 (Pubitemid 27227210)
8. Chan, D. C., Chutkowski, C. T., and Kim, P. S. (1998) Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc. Natl. Acad. Sci. U.S.A. 95, 15613-15617 (Pubitemid 29018748)
9. Chan, D. C., and Kim, P. S. (1998) HIV entry and its inhibition. Cell 93, 681-684 (Pubitemid 28257575)
10. Kilby, J. M., Hopkins, S., Venetta, T. M., DiMassimo, B., Cloud, G. A., Lee, J. Y., Alldredge, L., Hunter, E., Lambert, D., Bolognesi, D., Matthews, T., Johnson, M. R., Nowak, M. A., Shaw, G. M., and Saag, M. S. (1998) Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. 4, 1302-1307 (Pubitemid 28512112)
11. Lalezari, J. P., Henry, K., O'Hearn, M., Montaner, J. S., Piliero, P. J., Trottier, B., Walmsley, S., Cohen, C., Kuritzkes, D. R., Eron, J. J., Jr., Chung, J., DeMasi, R., Donatacci, L., Drobnes, C., Delehanty, J., and Salgo, M. (2003) Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N. Engl. J. Med. 348, 2175-2185 (Pubitemid 36618128)
12. Lazzarin, A., Clotet, B., Cooper, D., Reynes, J., Arastéh, K., Nelson, M., Katlama, C., Stellbrink, H. J., Delfraissy, J. F., Lange, J., Huson, L., DeMasi, R., Wat, C., Delehanty, J., Drobnes, C., Salgo, M., and TORO 2 Study Group (2003) Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N. Engl. J. Med. 348, 2186-2195 (Pubitemid 36618129)
13. Wild, C. T., Shugars, D. C., Greenwell, T. K., McDanal, C. B., and Matthews, T. J. (1994) Peptides corresponding to a predictive α-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. U.S.A. 91, 9770-9774 (Pubitemid 24311889)
14. Ashkenazi, A., Wexler-Cohen, Y., and Shai, Y. (2011) Multifaceted action of Fuzeon as virus-cell membrane fusion inhibitor. Biochim. Biophys. Acta 1808, 2352-2358
15. Rimsky, L. T., Shugars, D. C., and Matthews, T. J. (1998) Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J. Virol. 72, 986-993 (Pubitemid 28116876)
16. Wei, X., Decker, J. M., Liu, H., Zhang, Z., Arani, R. B., Kilby, J. M., Saag, M. S., Wu, X., Shaw, G. M., and Kappes, J. C. (2002) Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46, 1896-1905 (Pubitemid 34535213)
17. Greenberg, M. L., and Cammack, N. (2004) Resistance to enfuvirtide, the first HIV fusion inhibitor. J. Antimicrob. Chemother. 54, 333-340 (Pubitemid 39177450)
18. Naider, F., and Anglister, J. (2009) Peptides in the treatment of AIDS. Curr. Opin. Struct. Biol. 19, 473-482
19. Eggink, D., Berkhout, B., and Sanders, R. W. (2010) Inhibition of HIV-1 by fusion inhibitors. Curr. Pharm. Des. 16, 3716-3728
20. Steffen, I., and Pöhlmann, S. (2010) Peptide-based inhibitors of the HIV envelope protein and other class I viral fusion proteins. Curr. Pharm. Des. 16, 1143-1158
21. Berkhout, B., Eggink, D., and Sanders, R. W. (2012) Is there a future for antiviral fusion inhibitors? Curr. Opin. Virol. 2, 50-59
22. He, Y., Cheng, J., Li, J., Qi, Z., Lu, H., Dong, M., Jiang, S., and Dai, Q. (2008) Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure. Implications for designing novel anti-HIV fusion inhibitors. J. Virol. 82, 6349-6358 (Pubitemid 351875113)
23. He, Y., Cheng, J., Lu, H., Li, J., Hu, J., Qi, Z., Liu, Z., Jiang, S., and Dai, Q. (2008) Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains. Proc. Natl. Acad. Sci. U.S.A. 105, 16332-16337
24. Yao, X., Chong, H., Zhang, C., Qiu, Z., Qin, B., Han, R., Waltersperger, S., Wang, M., He, Y., and Cui, S. (2012) Structural basis of potent and broad HIV-1 fusion inhibitor CP32M. J. Biol. Chem. 287, 26618-26629
25. Chong, H., Yao, X., Qiu, Z., Qin, B., Han, R., Waltersperger, S., Wang, M., Cui, S., and He, Y. (2012) Discovery of critical residues for viral entry and inhibition through structural insight of HIV-1 fusion inhibitor CP621-652. J. Biol. Chem. 287, 20281-20289
26. Wexler-Cohen, Y., Johnson, B. T., Puri, A., Blumenthal, R., and Shai, Y. (2006) Structurally altered peptides reveal an important role for N-terminal heptad repeat binding and stability in the inhibitory action of HIV-1 peptide DP178. J. Biol. Chem. 281, 9005-9010 (Pubitemid 43864612)
27. He, Y., Liu, S., Jing, W., Lu, H., Cai, D., Chin, D. J., Debnath, A. K., Kirchhoff, F., and Jiang, S. (2007) Conserved residue Lys-574 in the cavity of HIV-1 Gp41 coiled-coil domain is critical for six-helix bundle stability and virus entry. J. Biol. Chem. 282, 25631-25639 (Pubitemid 47372795)
28. He, Y., Liu, S., Li, J., Lu, H., Qi, Z., Liu, Z., Debnath, A. K., and Jiang, S. (2008) Conserved salt bridge between the N- and C-terminal heptad repeat regions of the human immunodeficiency virus type 1 gp41 core structure is critical for virus entry and inhibition. J. Virol. 82, 11129-11139
29. Li, J., Chen, X., Huang, J., Jiang, S., and Chen, Y. H. (2009) Identification of critical antibody-binding sites in the HIV-1 gp41 six-helix bundle core as potential targets for HIV-1 fusion inhibitors. Immunobiology 214, 51-60
30. Jiang, S., Lin, K., and Lu, M. (1998) A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the human immunodeficiency virus type 1 envelope glycoprotein. J. Virol. 72, 10213-10217 (Pubitemid 28520893)
31. Buzon, V., Natrajan, G., Schibli, D., Campelo, F., Kozlov, M. M., and Weissenhorn, W. (2010) Crystal structure of HIV-1 gp41 including both fusion peptide and membrane proximal external regions. PLoS Pathog. 6, e1000880
32. Ingallinella, P., Bianchi, E., Ladwa, N. A., Wang, Y. J., Hrin, R., Veneziano, M., Bonelli, F., Ketas, T. J., Moore, J. P., Miller, M. D., and Pessi, A. (2009) Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency. Proc. Natl. Acad. Sci. U.S.A. 106, 5801-5806
33. Stoddart, C. A., Nault, G., Galkina, S. A., Thibaudeau, K., Bakis, P., Bousquet-Gagnon, N., Robitaille, M., Bellomo, M., Paradis, V., Liscourt, P., Lobach, A., Rivard, M. E., Ptak, R. G., Mankowski, M. K., Bridon, D., and Quraishi, O. (2008) Albumin-conjugated C34 peptide HIV-1 fusion inhibitor. Equipotent to C34 and T-20 in vitro with sustained activity in SCID-hu Thy/Liv mice. J. Biol. Chem. 283, 34045-34052
34. He, Y., Xiao, Y., Song, H., Liang, Q., Ju, D., Chen, X., Lu, H., Jing, W., Jiang, S., and Zhang, L. (2008) Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. J. Biol. Chem. 283, 11126-11134
35. Weng, Y., and Weiss, C. D. (1998) Mutational analysis of residues in the coiled-coil domain of human immunodeficiency virus type 1 transmembrane protein gp41. J. Virol. 72, 9676-9682 (Pubitemid 28520831)
36. Shu, W., Liu, J., Ji, H., Radigen, L., Jiang, S., and Lu, M. (2000) Helical interactions in the HIV-1 gp41 core reveal structural basis for the inhibitory activity of gp41 peptides. Biochemistry 39, 1634-1642 (Pubitemid 30108955)
37. Weng, Y., Yang, Z., and Weiss, C. D. (2000) Structure-function studies of the self-assembly domain of the human immunodeficiency virus type 1 transmembrane protein gp41. J. Virol. 74, 5368-5372 (Pubitemid 30313881)
38. Lu, M., Stoller, M. O., Wang, S., Liu, J., Fagan, M. B., and Nunberg, J. H. (2001) Structural and functional analysis of interhelical interactions in the human immunodeficiency virus type 1 gp41 envelope glycoprotein by alanine-scanning mutagenesis. J. Virol. 75, 11146-11156 (Pubitemid 33031581)
39. Sackett, K., Wexler-Cohen, Y., and Shai, Y. (2006) Characterization of the HIV N-terminal fusion peptide-containing region in context of key gp41 fusion conformations. J. Biol. Chem. 281, 21755-21762 (Pubitemid 44181879)
40. Dimitrov, A. S., Louis, J. M., Bewley, C. A., Clore, G. M., and Blumenthal, R. (2005) Conformational changes in HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion and inactivation. Biochemistry 44, 12471-12479 (Pubitemid 41324338)
41. Yao, X., Chong, H., Zhang, C., Waltersperger, S., Wang, M., Cui, S., and He, Y. (2012) Broad antiviral activity and crystal structure of HIV-1 fusion inhibitor Sifuvirtide. J. Biol. Chem. 287, 6788-6796
42. Otaka, A., Nakamura, M., Nameki, D., Kodama, E., Uchiyama, S., Nakamura, S., Nakano, H., Tamamura, H., Kobayashi, Y., Matsuoka, M., and Fujii, N. (2002) Remodeling of gp41-C34 peptide leads to highly effective inhibitors of the fusion of HIV-1 with target cells. Angew. Chem. Int. Ed. Engl. 41, 2937-2940
43. Naito, T., Izumi, K., Kodama, E., Sakagami, Y., Kajiwara, K., Nishikawa, H., Watanabe, K., Sarafianos, S. G., Oishi, S., Fujii, N., and Matsuoka, M. (2009) SC29EK, a peptide fusion inhibitor with enhanced α-helicity, inhibits replication of human immunodeficiency virus type 1 mutants resistant to enfuvirtide. Antimicrob. Agents Chemother. 53, 1013-1018
44. Dwyer, J. J., Wilson, K. L., Davison, D. K., Freel, S. A., Seedorff, J. E., Wring, S. A., Tvermoes, N. A., Matthews, T. J., Greenberg, M. L., and Delmedico, M. K. (2007) Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. Proc. Natl. Acad. Sci. U.S.A. 104, 12772-12777 (Pubitemid 47255230)
45. Eggink, D., Bontjer, I., Langedijk, J. P., Berkhout, B., and Sanders, R. W. (2011) Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 function. J. Virol. 85, 10785-10797